Gossamer Bio Statistics
Total Valuation
Gossamer Bio has a market cap or net worth of $151.14 million. The enterprise value is $63.88 million.
| Market Cap | 151.14M |
| Enterprise Value | 63.88M |
Important Dates
The next estimated earnings date is Tuesday, May 7, 2024, after market close.
| Earnings Date | May 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Gossamer Bio has 225.58 million shares outstanding. The number of shares has increased by 80.46% in one year.
| Shares Outstanding | 225.58M |
| Shares Change (YoY) | +80.46% |
| Shares Change (QoQ) | -20.87% |
| Owned by Insiders (%) | 2.25% |
| Owned by Institutions (%) | 93.17% |
| Float | 190.99M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.41 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.94, with a Debt / Equity ratio of 3.33.
| Current Ratio | 5.94 |
| Quick Ratio | n/a |
| Debt / Equity | 3.33 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -12.31 |
Financial Efficiency
Return on equity (ROE) is -944.80% and return on invested capital (ROIC) is -67.58%.
| Return on Equity (ROE) | -944.80% |
| Return on Assets (ROA) | -67.80% |
| Return on Capital (ROIC) | -67.58% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.33M |
| Employee Count | 135 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -40.18% in the last 52 weeks. The beta is 1.74, so Gossamer Bio's price volatility has been higher than the market average.
| Beta (1Y) | 1.74 |
| 52-Week Price Change | -40.18% |
| 50-Day Moving Average | 1.16 |
| 200-Day Moving Average | 0.98 |
| Relative Strength Index (RSI) | 20.45 |
| Average Volume (30 Days) | 1,342,098 |
Short Selling Information
The latest short interest is 11.11 million, so 4.93% of the outstanding shares have been sold short.
| Short Interest | 11.11M |
| Short Previous Month | 10.76M |
| Short % of Shares Out | 4.93% |
| Short % of Float | 5.82% |
| Short Ratio (days to cover) | 7.15 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -183.76M |
| Pretax Income | -179.82M |
| Net Income | -179.82M |
| EBITDA | -161.92M |
| EBIT | -166.31M |
| Earnings Per Share (EPS) | -$1.18 |
Balance Sheet
The company has $296.43 million in cash and $209.16 million in debt, giving a net cash position of $87.26 million or $0.39 per share.
| Cash & Cash Equivalents | 296.43M |
| Total Debt | 209.16M |
| Net Cash | 87.26M |
| Net Cash Per Share | $0.39 |
| Equity / Book Value | 62.77M |
| Book Value Per Share | 0.28 |
| Working Capital | 254.92M |
Cash Flow
| Operating Cash Flow | -159.16M |
| Capital Expenditures | n/a |
| Free Cash Flow | -159.16M |
| FCF Per Share | -$1.04 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Gossamer Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -80.46% |
| Shareholder Yield | -80.46% |
| Earnings Yield | -118.97% |
| FCF Yield | -105.31% |
Analyst Forecast
The average price target for Gossamer Bio is $8.60, which is 1,183.58% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.60 |
| Price Target Difference | 1,183.58% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |